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ABSTRACT	
OBJECTIVES:	 Transcatheter	 aortic	 valve	 implantation	 (TAVI)	 has	 been	 adopted	 rapidly	 in	 Europe	despite	
the	 paucity	 of	 randomized	 studies.	 TAVI	 registries	 represent	 a	 real-world	 scenario	 thus	 providing	 the	
evidence	 for	 the	 treatment	 of	 high-risk	 patients.	We	 undertook	 a	meta-analysis	 of	 published	 European	
national	TAVI	registries	to	assess	current	results	of	TAVI	technologies	in	Europe.		
METHODS:	 Electronic	databases	were	searched.	The	 review	 focused	on	 the	comparison	of	 the	 following	
TAVI	technologies:	transfemoral	(TF)	and	transapical	 (TA)	SAPIEN	and	Core	Valve	 implantation.	 Individual	
event	rates	for	outcomes	of	interest	were	pooled	using	a	mixed	effect	model.		
RESULTS:	A	total	of	7	European	national	TAVI	registries	(UK,	Swiss,	Belgium,	Italy,	Spain,	France,	Germany)	
were	identified	including	a	total	of	9786	patients	who	received	TF	SAPIEN		(n=2885),	TA	SAPIEN		(n=2252)	
and	Core	Valve	 (n=4649)	 implantation.	Pooled	 incidence	of	30	days	mortality	was	0.08	 [95%	Confidence	
Interval	(CI):	0.05-0.11],	0.12	[95%CI:	0.07-0.19]	and	0.06	[95%	CI:	0.03-0.11]	for	TF	SAPIEN,	TA	SAPIEN	and	
Core	 Valve	 respectively	 (test	 for	 subgroup	 difference	 P=0.18)	 and	 high	 heterogeneity	 across	 European	
country	 was	 found.	 Pooled	 incidence	 of	 stroke	 was	 comparable	 among	 the	 TAVI	 technologies	 (test	 for	
subgroup	difference	P=0.79)	as	well	as	the	incidence	of	post	procedure	paravalvular	leak	≥	2	(P=0.9).	Core	
Valve	 increased	 the	 likelihood	 of	 pacemaker	 implantation	 requirement	 (test	 for	 subgroup	 difference	
P<0.0001).	
CONCLUSIONS:	Trans-vascular	TAVI	approaches	were	associated	with	a	lower	early	mortality	regardless	of	
the	type	of	device	used.	There	was	a	marked	heterogeneity	among	European	countries	for	early	mortality.	
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INTRODUCTION	
Since	 Dr	 Alain	 Cribier	 pioneered	 the	 first	
transcatheter	 aortic	 valve	 implantation	 (TAVI)	
procedure	 in	 2002	 [1],	this	 relatively	 new	
technique	 has	 been	 used	 extensively	 in	 Europe.	
Based	 on	 the	 compelling	 evidence	 from	 the	
randomized	 Placement	 of	 Aortic	 Transcatheter	
Valves	 (PARTNER)	 A	 and	 B	 cohort	 [2,3],	 TAVI	 is	
now	considered	standard	of	care	for	extreme	risk	
and	 inoperable	 patients	 and	 is	 an	 alternative	 to	
surgery	 for	 high	 risk	 patients	 with	 symptomatic	
aortic	 stenosis	 [4].	 However,	 patients	 enrolled	
were	 highly	 selected,	 which	 does	 not	 reflect	 a	
clinical	 real-world	 situation.	 In	 a	 randomized	
controlled	 trial,	 it	 is	 reasonable	 to	 exclude	
patients	 presenting	 with	 co-morbidities	 or	
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anatomical	constraints	to	avoid	confounding,	but	
it	is	therefore	difficult	to	extend	the	major	finding	
of	 the	 study	 to	 a	 real-world	 patient	 population.	
Nevertheless,	 patients	 at	 high-risk	 or	 inoperable	
due	 to	 co-morbidities	 driving	 the	 surgical	 risk	
score	 or	 frailty	 are	 captured	 by	 mixed	 national	
registries,	 which	 therefore	 provide	 the	 evidence	
for	 the	 treatment	 of	 high-risk	 patients	 (with	 co-
morbidities	 and	 anatomical	 constraints)	 in	 daily	
clinical	practice	[4].		
Furthermore,	 mixed	 national	 registries	
report	 country	 specific	 results,	 which	 may	 be	
affected	 by	 variations	 in	 national	 health	 policy	
and	practice,	device	performance	and	definitions	
thus	 accounting	 for	 otherwise	 inexplicable	
differences	 in	 outcome	 and	 complications.	
Therefore,	we	 aimed	 to	 get	 insight	 into	 the	 role	
of	TAVI	in	the	treatment	of	high-risk	patients	with	
aortic	 stenosis	 in	 Europe	 by	 conducting	 a	meta-
analysis	 of	 European	 national	 registries	 focusing	
on	 three	 different	 TAVI	 technologies	 widely	
adopted:	 the	 transfemoral	 and	 transapical	
balloon-expandable	 Edwards	 SAPIEN	
transcatheter	heart	valve	 (Edwards	Life	sciences,	
Irvine,	 CA,	 USA)	 and	 the	 self-expanding	
Medtronic	 Core	 Valve	 (Medtronic,	 Minneapolis,	
MN,	USA).		
	
MATERIAL	AND	METHODS	
The	 present	 review	 was	 performed	
according	 to	 the	 Cochrane	 Collaboration	 and	
PRISMA	 statements	 [5].	 Studies	 included	 in	 the	
present	meta-analysis	met	 the	 following	criteria:	
(1)	 European	 national	 registry	 reporting	
outcomes	 of	 patients	 undergoing	 TAVI;	 (2)	
transfemoral	 (TF	 SAPIEN)	 and/or	 transapical	 (TA	
SAPIEN)	 balloon-expandable	 Edwards	 SAPIEN	
transcatheter	 heart	 valve	 and/or	 the	 self-
expanding	Medtronic	Core	Valve	were	used.	Non-
English	 language,	 review	 articles,	 and	 editorials	
were	 excluded.	 Care	 was	 taken	 to	 ensure	 that	
studies	 selected	 did	 not	 result	 in	 duplication	 of	
data.	Studies	that	did	not	separate	results	for	TF	
SAPIEN,	 TA	 SAPIEN	 and	 Core	 Valve	 were	
excluded.		
A	 literature	 search	 was	 done	 on	 1	
September	 2014	 using	 MEDLINE,	 EMBASE,	 and	
Web	 of	 Science	 to	 identify	 relevant	 articles.	
Search	terms	used	the	controlled	vocabularies	of	
MEDLINE	 and	 EMBASE	 alone	 or	 in	 combination	
with	 text	 words	 including	 "transcatheter	 aortic	
valve	 implantation",	"TAVI",	"registry",	"Europe".	
References	 from	 the	 selected	 studies	 were	 also	
manually	 searched	 to	 avoid	 missing	 any	
potentially	suitable	articles.	
Our	 primary	 endpoints	 were:	 mortality	
within	 30	 days	 and	 1	 year,	 incidence	 of	 stroke,	
pacemaker	 implantation,	 and	 aortic	 paravalvular	
leak	≥2.	Two	reviewers	(U.B.,	C.N.)	independently	
screened	all	 studies	 for	 inclusion.	Disagreements	
were	resolved	by	consensus.		
Statistical	 analysis:	 Agreement	 between	
reviewers	regarding	study	inclusion	was	assessed	
using	 the	 Cohen	 k	 statistic.	Mixed	 effects	meta-
analysis	 of	 single	 proportions	 using	 the	
DerSimonian-Laird	estimate	was	used	to	calculate	
overall	 proportions	 of	 outcomes	 using	 different	
TAVI	 technologies.	 I2	 statistic	 was	 used	 to	
estimate	the	percentage	of	total	variation	across	
studies,	 which	 is	 due	 to	 heterogeneity	 rather	
than	 chance.	 Suggested	 thresholds	 for	
heterogeneity	were	used,	with	I2	values	of	25%	to	
49%,	50%	to	74%,	and	75%	or	greater,	 indicative	
of	 low,	 moderate,	 and	 high	 heterogeneity	 [6].	
Cochrane	 Q	 statistic	 was	 used	 as	 test	 for	
subgroup	differences	(random	effects	model).		By	
means	 of	 multivariate	 meta-regression	 (mixed	
effect	 model),	 the	 effect	 of	 different	 TAVI	
technologies	 on	 investigated	 outcomes	 was	
adjusted	 for	 the	 following	 confounding	 factors:	
average	patient	risk	profile	using	average	Logistic	
Euroscore	[7],	European	country,	total	number	of	
centres	involved	and	funding	by	manufacturer.	R2	
was	 used	 to	 estimate	 the	 amount	 of	
heterogeneity	 accounted	 for	 in	 the	 mutivariate	
model.	Publication	bias	was	assessed	using	Begg	
&	Mazumdar	test.	Trim-and-fill	method	was	used	
for	estimating	and	adjusting	 for	 the	number	and	
outcomes	of	missing	studies.	A	P	value	 less	 than	
0.05	was	used	as	the	level	of	significance	and	95%	
confidence	 intervals	 (95%CI)	have	been	reported	
where	appropriate.	R	version	3.1.0	(R	Core	Team	
(2014).	 R:	 A	 language	 and	 environment	 for	
statistical	computing.	R	Foundation	for	Statistical	
Computing,	 Vienna,	 Austria.	 URL	 http://www.R-
project.org/)	and	meta	package	(Guido	Schwarzer	
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(2014).	 meta:	 Meta-Analysis	 with	 R.	 R	 package	
version	 3.7-1.	 http://CRAN.R-
project.org/package=meta)	 were	 used	 for	 all	
statistical	analyses.			
	
Results	
	
Studies	selection		
From	 1,079	 abstracts,	 we	 selected	 108	
full-text	articles	that	were	assessed	for	eligibility.	
After	evaluating	the	full-text	articles,	8	fitted	our	
selection	criteria	and	were	finally	selected	for	the	
systematic	 review	 and	 meta-analysis	 [8-15].	
Studies	 overview	 is	 summarized	 in	 Table	 1.	 An	
outline	 of	 the	 systematic	 review	 process	 is	
depicted	 in	 Figure	 1.	 A	 Cohen	 k	 statistic	 of	 90%	
was	obtained	for	the	final	selection	process.		
A	 total	 of	 7	 European	 national	 TAVI	 registries	
(Belgium,	 France,	 Germany,	 Italy,	 Spain,	 Swiss,	
UK)	 were	 identified	 including	 a	 total	 of	 9786	
patients	 who	 received	 TF	 SAPIEN	 	 (n=2885),	 TA	
SAPIEN	 	 (n=2252)	 and	 Core	 Valve	 (n=4649)	
implantation.	 All	 but	 Italian	 and	 Swiss	 registries	
reported	 on	 the	 three	 technologies.	 Two	
different	 Italian	 TAVI	 registries	 reported	 on	 TA	
SAPIEN	 and	 Core	 Valve	 implantation	 separately.	
The	 Swiss	 registry	 reported	 on	 TF	 SAPIEN	 and	
Core	 Valve	 only.	 	 Average	 logistic	 EuroSCORE	
ranged	 from	 16%	 (Spain	 registry,	 Core	 Valve	
group)	 to	 33%	 (Belgian	 registry,	 TA	 SAPIEN	
group).			
	
30-day	mortality		
Pooled	 estimate	 for	 the	 incidence	 of	 30-
day	 mortality	 (Figure	 2)	 was	 0.08	 [95%CI:	 0.05-
0.11],	 0.12	 [95%CI:	 0.07-0.19]	 and	 0.06	 [95%CI:	
0.03-0.11]	 for	 TF	 SAPIEN™,	 TA	 SAPIEN	 and	 Core	
Valve	respectively	(test	for	subgroup	difference	P	
=	0.18).	High	heterogeneity	among	registries	was	
found	for	TF	SAPIEN		(I2	=	86.6%),	TA	SAPIEN		(I2	=	
93.3%)	and	Core	Valve	(I2	=	97%)	technologies.	No	
publication	 bias	 was	 detected	 (P	 =	 0.31).	
Multivariate	 meta-regression	 found	 that	 TA	
SAPIEN	technology	(b	coefficient	0.60;	P	=	0.001)	
and	 number	 of	 centres	 involved	 (b	 coefficient	
0.14;	 P	 =	 0.03)	 were	 independently	 associated	
with	an	increased	risk	of	30-day	mortality.	On	the	
other	 hand,	 TAVI	 performed	 in	 Spain	 (b	
coefficient	 -4.3;	P	=	0.03),	 in	 Italy	 (b	coefficient	 -
2.1;	 P	 <	 0.0001),	 in	 UK	 (b	 coefficient	 -1.95;	 P	 =	
0.01)	 and	 in	 France	 (b	 coefficient	 -2.8;	 P	 =	 0.03)	
were	 associated	 with	 a	 lower	 30-day	 mortality.	
Patients	 risk	 profile	 assessed	 by	 the	 average	
Logistic	 EuroSCORE	was	 not	 associated	 with	 30-
day	mortality	 (P	 =	 0.9).	 	Moderators	 included	 in	
the	 multivariate	 model	 accounted	 for	 98%	
amount	 of	 heterogeneity	 with	 no	 significant	
residual	heterogeneity	(P	=	0.25).			
	
Stroke	
Pooled	 estimate	 for	 the	 incidence	 of	
stroke	 (Figure	 3)	 was	 0.03	 [95%CI:	 0.03-0.04],	
0.03	 [95%CI:	 0.02-0.05]	 and	 0.03	 [0.02-0.04]	 for	
TF	 SAPIEN™,	 TA	 SAPIEN	 and	 Core	 Valve	
respectively	 (test	 for	 subgroup	 difference	 P	 =	
0.79).	 High	 heterogeneity	 was	 found	 among	
registries	 for	 TA	 SAPIEN	 	 (I2	 =	 81.2%)	 whilst	 TF	
SAPIEN	and	Core	Valve	were	associated	with	low	
heterogeneity	 for	 stroke	 incidence	 (I2=0%	 and	
I2=32.6%	 respectively).	 No	 publication	 bias	 was	
detected	(P	=	0.27).	Multivariate	meta-regression	
found	 that	 procedures	 performed	 in	 Italy	 only	
were	 independently	 associated	 with	 a	 lower	
incidence	of	 stroke	 (b	 coefficient	 -1.5;	P	=	0.02).	
Patients	 risk	 profile	 assessed	 by	 the	 average	
Logistic	 EuroSCORE	was	 not	 associated	with	 the	
incidence	 of	 stroke	 (P	 =	 0.74).	 Moderators	
included	in	the	multivariate	model	accounted	for	
82.4%	 amount	 of	 heterogeneity	 with	 no	
significant	residual	heterogeneity	(P	=	0.32).			
	
Need	for	pacemaker	implantation	
Pooled	 estimate	 for	 incidence	 of	
pacemaker	 implantation	 (Figure	 4)	 was	 0.08	
[95%CI:	 0.05-0.11],	 0.07	 [95%CI:	 0.04-0.11]	 and	
0.22	 [95%CI:	 0.19-0.26]	 for	 TF	 SAPIEN™,	 TA	
SAPIEN	 and	 Core	 Valve	 respectively	 (test	 for	
subgroup	 difference	 P	 <	 0.0001).	 High	
heterogeneity	was	found	among	registries	for	TF	
SAPIEN		(I2	=	80.9%),	TA	SAPIEN		(I2	=	88.8%)	and	
Core	Valve	(I2	=	83%)	technologies.	No	publication	
bias	was	detected	 (P	=	0.08).	Multivariate	meta-
regression	 found	 that	TF	SAPIEN	 	 (b	coefficient	 -
1.2;	 P	 <	 0.0001)	 and	 TA	 SAPIEN	 	 (b	 coefficient	 -
1.08;	 P	 =	 0.001)	 were	 independently	 associated	
with	 a	 lower	 risk	 of	 pacemaker	 implantation.
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Table	1:	Registries	overview	
Registry	(1)	 Period	 N	 TAVI	technology	 n	
Logistic	
Euro	SCORE	
	
Belgian	National	TAVI	Registry	[8].	
	 2007-2010	 15	
SAPIEN	TF	 99	 29	
SAPIEN	TA	 88	 33	
Core	Valve	 141	 25	
FRANCE	2	TAVI	Registry	[9]	
	 2010-2011	 34	
SAPIEN	TF	 1540	 22.2	
SAPIEN	TA	 567	 24.8	
Core	Valve	 1043	 21.3	
German	TAVI	Registry	[10]	
	 2009-2010	 22	
SAPIEN	TF	 123	 20.3	
SAPIEN	TA	 113	 20.3	
Core	Valve	 1074	 20.3	
Italian	Registry	TA	TAVI	[11]	
	 2008-2012	 21	 SAPIEN	TA	 774	 25.6	
Italian	Multicentre	Core	Valve	Registry	[12]	
	 2007-2009	 14	 Core	Valve	 659	 23	
Spain	TAVI	Registry	[13].	
	 2010-2011	 44	
SAPIEN	TF	 504	 17	
SAPIEN	TA	 302	 19.2	
Core	Valve	 610	 16	
SWISS	TAVI	Registry	[14]	
	 2011-2013	 8	
SAPIEN	TF	 232	 20.2	
Core	Valve	 324	 20.2	
UK	TAVI	Registry	[15]	
	 2007-2010	 30	
SAPIEN	TF	 387	 17.7	
SAPIEN	TA	 408	 22.5	
Core	Valve	 798	 20.25	
	
N=	number	of	participating	centres,	TAVI	=	transcatheter	aortic	valve	implantation;	n	=	number	of	patients,	
TF	=	transfemoral;	TA	=	transapical;	UK	=	United	Kingdom,	(1)	=	all	 registries	stated	being	funded	by	the	
manufacturer	except	[8]	and	[13].	
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Figure	1.	Outline	of	the	systematic	review	process	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Patients	 risk	 profile	 assessed	 by	 the	 average	
Logistic	 EuroSCORE	was	 not	 associated	with	 the	
rate	 of	 pacemaker	 implantation	 (P	 =	 0.78).	
Moderators	 included	 in	 the	 multivariate	 model	
accounted	 for	 90.5%	 amount	 of	 heterogeneity	
but	 significant	 residual	 heterogeneity	was	 found	
(P	=	0.02).	
	
Aortic	paravalvular	leak		
Pooled	 estimate	 for	 the	 incidence	 of	
aortic	 paravalvular	 leak	 ≥2	 (Figure	 5)	 was	 0.07	
[95%CI:	 0.05-0.11],	 0.06	 [95%CI:	 0.05-0.08]	 and	
0.07	 [95%CI:	 0.04-0.12]	 for	 TF	 SAPIEN™,	 TA	
SAPIEN	 and	 Core	 Valve	 respectively	 (test	 for	
subgroup	difference	P	=	0.9).	High	heterogeneity	
was	 found	 among	 registries	 for	 TF	 SAPIEN	 	 (I2	 =	
84.7%)	and	Core	Valve	(I2	=	94.4%)	but	not	for	TA	
SAPIEN	 	 (I2	 =	 29.1%)	 but	 significant	 publication	
bias	 was	 detected	 (P	 =	 0.002).	 Trim	 and	 fill	
method	suggested	an	overall	prevalence	of	aortic	
paravalvular	leak	of	0.10	[95%CI:	0.0767-0.131]	
1-year	mortality	
Pooled	 estimate	 for	 incidence	 of	 1-year	
mortality	(Figure	6)	was	0.15	[95%	CI:	0.14-0.16],	
0.23	 [95%CI:	 0.19-0.28]	 and	 0.17	 [95%CI:	 0.15-
0.19]	for	TF	SAPIEN™,	TA	SAPIEN	and	Core	Valve	
respectively	 (test	 for	 subgroup	 difference	 P	 =	
0.0008).	 High	 heterogeneity	 was	 found	 among	
registries	 for	 TA	 SAPIEN	 	 (I2	 =	 81.9%)	 and	 Core	
Valve	(I2	=	59.3%)	but	not	for	TF	SAPIEN		(I2	=	0%).	
No	 publication	 bias	 was	 detected	 (P	 =	 0.25).	 At	
multivariate	meta-regression,	Logistic	EuroSCORE	
was	moderately	associated	with	1-year	mortality	
(b	 coefficient	 0.07;	 P	 =	 0.06,).	 TAVI	 technologies	
did	 not	 impact	 on	 1	 year	 mortality	 (TF	 SAPIEN	
versus	Core	Valve	(b	coefficient	-0.1428;	P	=	0.07)	
and	 TA	 SAPIEN	 versus	 Core	 Valve	 (b	 coefficient	
0.1515;	 P	 =	 0.3).	 	 Moderators	 included	 in	 the	
multivariate	model	 accounted	 for	 100%	 amount	
of	 heterogeneity	 and	 no	 significant	 residual	
heterogeneity	was	found	(P	=	0.48).	
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Figure	2:	Meta-analysis	for	proportion	of	30-day	mortality.
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	3.	Meta-analysis	for	proportions	of	stroke	
	
	Annals	of	Cardiovascular	and	Thoracic	Academy	(ACTA)	2015;	December	18:	1-11.																																																																	M	Zeinah,	M	Elghanam	and	U	Benedetto.	Original	article	–	Adult	Cardiac	surgery.	
Printed	by	Cardiovascular	&	Thoracic	Academy,	Faculty	of	Medicine,	Ain	Shams	University,	Cairo,	Egypt 
7 
Figure	4.	Meta-analysis	for	proportions	of	pacemaker	requirement	
	
	
	
Figure	5.	Meta-analysis	for	proportions	of	Incidence	of	paravalvular	leak	≥	2	
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Figure	6.	Meta-analysis	for	proportions	of	1-year	mortality	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Discussion	
The	main	finding	of	the	present	study	was	
that	 in	 the	 European	 real	 world	 practice,	 trans-
vascular	TAVI	approaches	were	associated	with	a	
lower	 early	 mortality	 regardless	 of	 the	 type	 of	
device	 used	 and	 did	 not	 increase	 the	 risk	 of	
stroke	or	significant	paravalvular	leak.	Core	Valve	
technology	 was	 associated	 with	 >	 2	 folds	
increased	risk	for	pacemaker	implantation.	There	
was	 a	 marked	 heterogeneity	 among	 European	
countries	 for	 all	 short-term	 outcomes	
investigated	 and	 we	 found	 an	 association	
between	30-day	mortality	and	European	country	
where	 the	 procedure	 was	 performed.	 Of	 note	
Logistic	 Euro	 SCORE	 which	 is	 widely	 adopted	 in	
Europe	to	discriminate	high-risk	patients	suitable	
for	TAVI,	 failed	 to	predict	early	mortality	 (within	
30	days)	but	it	presented	a	moderate	association	
with	 1-year	 mortality.	 Despite	 crude	 1	 year	
mortality	was	higher	among	patients	receiving	TA	
SAPIEN	 technology,	 this	 effect	 was	 no	 longer	
present	when	adjusted	for	patients’	risk	profile.		
Based	 on	 the	 compelling	 evidence	 of	 the	
randomized	 Placement	 of	 Aortic	 Transcatheter	
Valves	 (PARTNER)	 A	 and	 B	 cohort	 [2,3],	 TAVI	 is	
now	considered	standard	of	care	for	extreme	risk	
and	 inoperable	 patients	 in	 Europe	 and	 is	 an	
alternative	 to	 surgery	 for	 high-risk	 patients	with	
symptomatic	 aortic	 stenosis	 [4].	 However,	 the	
major	 drawback	 of	 PARTNER	 is	 the	 highly	
selected	 study	 cohort	 that	 does	 not	 reflect	 the	
daily	 clinical	practice.	TAVI	 registries	 represent	a	
real-world	scenario,	and	therefore	might	provide	
the	 evidence	 for	 the	 treatment	 of	 high-risk	
patients.		In	the	PARTNER	trial	A,	30-day	mortality	
was	3.4%	and	6.5%	for	TF	TAVI	and	surgical	aortic	
valve	 replacement	 respectively.	 In	PARTNER	 trial	
B,	 30-day	 mortality	 was	 5%	 after	 TAVI.	 In	 the	
STACCATO	trial	[16],	30-day	mortality	was	5.8%	in	
TA	 SAPIEN	 TAVI	 group.	 The	 present	 analysis	
showed	that	in	the	real	European	clinical	practice	
30-day	mortality	for	TAVI	(8%)	is	higher	than	that	
observed	 in	 randomized	 trials	 particularly	 after	
TA	 approach	 (12%)	 and	 this	 reflects	 the	 higher	
risk	 profile	 of	 unselected	 patients	 in	 the	 daily	
practice.	 Interestingly,	 the	 mortality	 rate	 in	 the	
TA	 cohort	 is	 not	 consistent	 with	 a	 number	 of	
published	 series	 [17,18],	 which	 deserves	 careful	
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examination	 in	 order	 to	 identify	 the	 reasons	 for	
this	discrepancy.		
Despite	we	attempted	to	adjust	the	effect	
of	 TAVI	 technologies	 on	 early	 mortality	 for	
patients	 risk	 profile	 using	 logistic	 Euro	 SCORE,	 a	
substantial	 selection	 bias	 resulting	 from	 the	
inclusion	 of	 patients	 with	 a	 higher	 co-morbidity	
rate	(mainly	peripheral	disease)	in	the	TA	SAPIEN	
group	 might	 partially	 explain	 the	 higher	 risk	 of	
early	 mortality	 observed.	 Of	 note,	 logistic	 Euro	
SCORE	was	not	associated	with	30-day	mortality	
in	 the	 present	 analysis.	 It	 is	 widely	 recognized	
that	 the	 logistic	 Euro	 SCORE	 is	 not	 an	 ideal	 tool	
for	measuring	the	pre	procedural	risk	of	TAVI,	as	
the	 predicted	mortality	 is	 grossly	 overestimated	
[19].		
The	 present	 analysis	 found	 that	 early	
mortality	 after	 TAVI	 varied	 significantly	 across	
European	 countries	 regardless	 of	 the	 type	 of	
technology	 used	 and	 the	 patients	 risk	 profile	
according	 to	 the	 logistic	 Euro	 SCORE.	 These	
discrepancies	 might	 be	 partially	 explained	 by	
different	policies	 in	patient	selection	and	patient	
risk	profile	not	accounted	for	by	the	logistic	Euro	
SCORE.	However,	heterogeneity	in	early	mortality	
across	 European	 countries	 highlights	 the	 urgent	
need	 for	 standardized	 criteria	 for	 patient	
selection.		
The	 incidence	 of	 stroke	 after	 TAVI	 in	 the	
PARTENR	A,	PARTNER	B	and	the	STACCATO	trials	
was	 5.5%,	 6.7%	 and	 8.8%	 respectively.	 In	 the	
European	 real-world	 clinical	 practice	 the	
incidence	of	stroke	at	≤	30	days	was	relatively	low	
3.0%	 without	 any	 difference	 among	 TAVI	
technologies.	 This	 result	 is	 particularly	
encouraging	considering	the	risk	of	perioperative	
stroke	 following	 surgical	 AVR	 in	 elderly	 patients	
ranges	 from	 3	 to	 7%.	 [20]	 Careful	 patient	
selection,	 device	 preparation,	 optimal	 device	
progression,	and	positioning,	as	well	as	adequate	
anti-platelet	 pre-medication	 and	 anticoagulation	
regimen	are	likely	to	reduce	this	risk.		
This	 analysis	 confirmed	 that	 Core	 Valve	
technology	is	associated	with	an	increased	rate	of	
pacemaker	 implantation	 than	 SAPIEN	
technologies	 (8%).	 However,	 the	 rate	 of	
pacemaker	 implantation	 in	 patients	 receiving	
SAPIEN	 technologies	 was	 higher	 than	 those	
reported	 in	 the	 PARTNET	 trial	 A	 (3.8%)	 and	 B	
(3.4%)	 and	 probably	 this	 aspect	 reflect	 an	
increased	 anatomic	 complexity	 for	 TAVI	 in	 the	
real-world	practice.		
The	incidence	of	paravalvular	leak	≥	2	was	
7%	 across	 European	 countries	 and	 this	 result	 is	
better	 than	 that	 reported	 in	PARTNER	A	 (12.2%)	
and	 B	 (11.8%)	 trials.	 This	 result	 seems	 to	 be	
encouraging	 due	 to	 the	 potential	 detrimental	
effect	 of	 post	 procedural	 paravalvular	 leak	 on	
outcomes	 [21].	 However,	 the	 absence	 of	
standardized	 definition	 and	 protocols	 to	 detect	
(i.e.	 angiography	 versus	 echocardiography)	 and	
score	 (qualitative	 or	 semi	 quantitative	methods)	
the	 incidence	of	 leak	 limits	definitive	conclusion.	
Moreover,	 the	 present	 analysis	 did	 not	 confirm	
the	protective	effect	of	 the	SAPIEN	valve	against	
post-procedural	 moderate	 to	 severe	 aortic	
regurgitation	 previously	 described	 although	 this	
information	was	omitted	in	some	registries.	
Finally,	in	the	European	real-world	clinical	
practice,	one-year	survival	 seems	more	“patient-
related”	 rather	 than	 “procedure-related.”	 Of	
note,	despite	the	logistic	Euro	SCORE	was	unable	
to	 predict	 early	 mortality,	 it	 was	 the	 only	
moderator	 marginally	 associated	 with	 1	 year	
mortality	across	European	national	registries.		
In	 conclusion,	 in	 the	European	 real	world	
practice	TAVI	is	associated	with	a	higher	mortality	
than	 that	 reported	 in	 randomized	 trials.	 This	
result	is	mainly	related	with	the	higher	risk	profile	
of	 non-selected	 patients	 currently	 referred	 for	
TAVI.	 However,	 according	 to	 the	 results	 of	 this	
meta-analysis,	 TA	 TAVI	 results	 are	 still	
unsatisfactory	and	 trans	vascular	TAVI	 should	be	
considered	as	the	first	line	approach.	Our	analysis	
confirms	 that	 the	 only	 real	 difference	 in	
outcomes	between	the	2	trans	vascular	devices	is	
the	 requirement	 for	 permanent	 pacemaker.	 The	
significant	heterogeneity	in	early	mortality	across	
European	countries	suggests	the	urgent	need	for	
standardization	 of	 patient	 selection	 process	 and	
procedural	 aspects	 in	 order	 to	 optimise	
outcomes,	 resource	 consumption	 and	 to	
guarantee	 high	 standards	 of	 care	 across	
European	 countries.	 Despite	 the	 fact	 that	 in	
Europe	 patients	 are	 currently	 selected	 for	 TAVI	
on	the	basis	of	their	surgical	risk	measured	by	the	
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logistic	 Euro	 SCORE	 (≥20%),	 such	 a	 risk	
stratification	 system	 is	 ineffective	 in	 predicting	
early	mortality	after	TAVI	in	daily	clinical	practice.	
Therefore,	 there	 is	 also	 an	 urgent	 need	 to	
develop	 a	 TAVI	 risk	 score	 for	 patient	 selection.	
European	TAVI	 registries	might	provide	powered	
sample	 sized	 TAVI	 populations	 to	 be	 used	 to	
generate	a	"tailored"	TAVI	risk	score.	However,	to	
collect	data	on	such	 large	numbers	of	patients	 it	
will	 be	 necessary	 to	 standardize	 definitions	 and	
clinical	end	points	after	TAVI.		
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